OTCMKTS:VRACY - Viralytics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.75 +0.49 (+15.03 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$3.75
Today's Range$3.75 - $3.75
52-Week Range$1.4999 - $4.10
Volume1,000 shs
Average Volume383 shs
Market Capitalization$261.48 million
P/E RatioN/A
Dividend YieldN/A
Viralytics logoViralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

Receive VRACY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRACY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.88 million
Price / Sales61.64
Cash FlowN/A
Price / CashN/A
Book Value$0.37 per share
Price / Book10.14


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares80,210,000

The Truth About Cryptocurrencies

Viralytics (OTCMKTS:VRACY) Frequently Asked Questions

What is Viralytics' stock symbol?

Viralytics trades on the OTCMKTS under the ticker symbol "VRACY."

Who are some of Viralytics' key competitors?

Who are Viralytics' key executives?

Viralytics' management team includes the folowing people:
  • Dr. Malcolm L. McColl BVSc (Hons), MBA, MD, CEO & Exec. Director
  • Mr. Robert Vickery, Chief Financial Officer
  • Prof. Darren Shafren B.Sc (Hons I) Ph.D., Chief Scientific Officer
  • Dr. Jennifer Rosenthal Ph.D., Director of Regulatory Affairs
  • Ms. Rae Saltzstein, Director of CMC Operations

Has Viralytics been receiving favorable news coverage?

Media coverage about VRACY stock has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viralytics earned a news impact score of 0.04 on Accern's scale. They also assigned news stories about the company an impact score of 45.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Viralytics?

Shares of VRACY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viralytics' stock price today?

One share of VRACY stock can currently be purchased for approximately $3.75.

How big of a company is Viralytics?

Viralytics has a market capitalization of $261.48 million and generates $4.88 million in revenue each year. The company earns $-9,260,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How can I contact Viralytics?

Viralytics' mailing address is 66 HUNTER STREET SUITE 305 LEVEL 3, SYDNEY C3, NSW2000. The company can be reached via phone at 029-988-4000 or via email at [email protected]

MarketBeat Community Rating for Viralytics (VRACY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Viralytics and other stocks. Vote "Outperform" if you believe VRACY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRACY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.